Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

I doubt Merck will fail to meet that mark. However, I also doubt the company will confound expectations with a strong quarter. It may take time to bring Winrevair up to speed commercially ...

The company released its financial results for the third quarter on Thursday, showing revenue had declined by 15 percent compared with the same quarter last year PAWTUCKET, R.I. — As Hasbro ...

Pharmaceutical titan Merck pays investors ... later this decade that has investors worried about Merck's growth prospects. But the company has been innovating, and regulators recently approved ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired ... New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).